Chronic Obstructive Lung Disease News and Research

RSS

European Commission and Japan approve once-daily dual bronchodilator Ultibro Breezhaler (QVA149) nearly simultaneously, for COPD patients

Novartis announced today that the European Commission approved once-daily Ultibro® Breezhaler® (indacaterol 85 mcg / glycopyrronium 43 mcg) as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD). In addition, the Japanese Ministry of Health, Labour and Welfare (MHLW) approved once-daily Ultibro® Inhalation Capsules (glycopyrronium 50 mcg / indacaterol 110 mcg), delivered through the Breezhaler® device, for relief of various symptoms due to airway obstruction in chronic obstructive pulmonary disease (COPD). Ultibro® Breezhaler® / Ultibro® Inhalation Capsules were developed under the name QVA149.

23 Sep 2013

Dual-pronged approach to diabetes and COPD needed

Researchers from the USA have found that patients with diabetes and a history of smoking have significantly impaired lung function, even in the absence of overt chronic obstructive pulmonary disease.

17 Sep 2013

Patients with COPD show improvements in lung function with olodaterol

Data from the olodaterol Phase 3 clinical program, presented for the first time at the European Respiratory Society (ERS) Annual Congress 2013 in Barcelona, showed the addition of olodaterol 5 and 10 µg delivered once daily via the Respimat® inhaler provided improvements in lung function in patients with moderate to very severe chronic obstructive pulmonary disease (COPD).

10 Sep 2013

Once-daily COPD portfolio data from Novartis presented at European Respiratory Society (ERS) Annual Congress

Novartis announced new analyses of data for once-daily Ultibro® Breezhaler® (investigational QVA149 - indacaterol 85 mcg/glycopyrronium 43 mcg delivered dose, equivalent to 110 mcg/50 mcg metered dose per capsule), which showed significant improvements in lung function, shortness of breath and health-related quality of life for chronic obstructive pulmonary disease (COPD) patients versus all comparators1,2. These data were part of 39 respiratory abstracts presented at the European Respiratory Society (ERS) Annual Congress in Barcelona, Spain.

9 Sep 2013

Investigators link acute viral infections to development of COPD

Investigators at Washington University School of Medicine in St. Louis have described another link in the chain of events that connect acute viral infections to the development of chronic obstructive pulmonary disease (COPD).

16 Aug 2013

CHMP gives positive opinion for approval of once-daily QVA149 for treatment of COPD

Sosei Group Corporation confirms the information released by Novartis that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for approval of once-daily Ultibro® Breezhaler®, as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).

29 Jul 2013

Elevated levels of inflammatory biomarkers in individuals associated with high risk of COPD exacerbations

Simultaneously elevated levels of the biomarkers C-reactive protein, fibrinogen and leukocyte count in individuals with chronic obstructive pulmonary disease (COPD) were associated with increased risk of having exacerbations, even in those with milder COPD and in those without previous exacerbations, according to a study in the June 12 issue of JAMA.

12 Jun 2013

Researchers find that over 40% of patients treated for COPD did not actually have the disease

More than 40 percent of patients being treated for COPD at a federally funded clinic did not have the disease, researchers found after evaluating the patients with spirometry, the diagnostic "gold standard" for chronic obstructive pulmonary disease.

23 May 2013

GOLD predicts mortality in COPD

The Global Initiative for Chronic Obstructive Lung Disease classification of chronic obstructive pulmonary disease predicts mortality better than the 2011 ABCD scoring system, report Norwegian researchers.

30 Apr 2013

Gas transfer predicts survival in lung disease patients

Gas transfer is the best lung function predictor of survival in patients with chronic obstructive pulmonary disease, study results suggest.

25 Feb 2013

Bronchiectasis finding reveals COPD patients at mortality risk

Bronchiectasis is independently associated with mortality risk among patients with moderate-to-severe chronic obstructive pulmonary disease, Spanish research shows.

12 Feb 2013

Bronchiectasis independently associated with increased mortality risk in COPD patients

Bronchiectasis is independently associated with an increased mortality risk in patients with moderate-to-severe COPD, according to a new study from researchers in Spain.

10 Feb 2013

COPD underdiagnosed in Chinese lung cancer patients

Chronic obstructive pulmonary disease is underdiagnosed and undertreated among lung cancer patients in China, study results show.

4 Feb 2013

Call for more COPD screening for smokers

Screening smokers with spirometry for chronic obstructive pulmonary disease picks up more cases than symptom-based detection, research suggests.

22 Jan 2013

Bladder cancer risk associated with childbearing factors

The risk for bladder cancer in women may decline with increased parity and older age at first birth, researchers report.

21 Jan 2013

New once-daily dual bronchodilator effective in COPD

A once-daily, inhaled, fixed-dose dual bronchodilator combination has greater efficacy than twice-daily salmeterol plus fluticasone for the treatment of chronic obstructive pulmonary disease, results of the phase III ILLUMINATE trial show.

18 Dec 2012

Sputum color guides antibiotic treatment in COPD

Withholding antibiotic treatment from hospitalized chronic obstructive lung disease patients with nonpurulent sputum does not negatively affect outcomes, a pilot study shows.

4 Dec 2012

Acute cough should raise asthma alarm

Around one-fifth of patients consulting their primary care physician for acute cough could have undiagnosed asthma or chronic obstructive pulmonary disease, show the results of a pan-European study.

20 Nov 2012

EC approves Sosei’s Seebri Breezhaler to treat COPD

Sosei Group Corporation confirms the information released today by Novartis that the European Commission has approved Seebri Breezhaler (glycopyrronium bromide) 44 mcg delivered dose (equivalent to 50 mcg glycopyrronium measured dose per capsule), as a once-daily inhaled maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).

1 Oct 2012

Japanese MHLW approves Sosei’s Seebri inhalation capsules to treat COPD

Sosei Group Corporation confirms the information released today by Novartis that the Japanese Ministry of Health, Labor and Welfare (MHLW) has approved Seebri (glycopyrronium bromide) Inhalation Capsules 50 mcg administered through the Breezhaler device, as a once-daily, long-term, inhaled maintenance bronchodilator treatment for the relief of various symptoms due to airway obstructive disease in chronic obstructive pulmonary disease.

28 Sep 2012